文献速递冠心病

年龄与稳定性冠心病PCI疗效的关联:ORBITA-2二次分析

Association Between Age and PCI Effectiveness in Stable CAD: Secondary Analysis of ORBITA-2.
PubMed 文献 · J Am Coll Cardiol · 2026-01-01

该研究为ORBITA-2试验的事后分析,评估年龄与症状及狭窄严重程度的关系,以及年龄对PCI疗效的影响。结果显示,老年患者PCI缓解症状的获益更大,而年轻患者运动耐量改善更明显,提示应关注年龄对PCI疗效终点的影响。

要点

  • 老年患者PCI缓解心绞痛的获益大于年轻患者。
  • 年轻患者PCI改善运动耐量的效果远优于老年患者。
  • 老年患者运动耐量改善有限,挑战其作为抗心绞痛试验主要终点的地位。

核心结论

  • PCI在所有年龄段均能有效减少心绞痛发作频率。
  • 老年患者运动耐量改善有限,挑战其作为抗心绞痛试验主要终点的角色。

研究设计与样本

  • ORBITA-2试验的事后分析,纳入所有参与ORBITA-2的患者。
  • 采用贝叶斯纵向马尔可夫模型分析每日症状,贝叶斯有序比例优势模型分析运动耐量等指标。

主要发现

  • 平均年龄64±9岁,范围40至82岁,年龄与症状及狭窄严重程度关系不大。
  • 老年患者PCI缓解症状的OR为2.03(95% CrI 1.67-2.45;Pr > 0.99),年轻患者OR为1.70(95% CrI 1.38-2.15;Pr > 0.99),交互作用Pr=0.99。
  • 50岁患者PCI改善运动耐量+125秒(95% CrI 35.8-215.0秒;Pr > 0.99),70岁患者+31.9秒(95% CrI -12.6至78.3;Pr=0.92),交互作用Pr=0.96。

临床怎么用

  • 对于老年稳定性冠心病患者,PCI可有效缓解心绞痛症状。
  • 在评估PCI疗效时,应考虑年龄对运动耐量改善的影响,老年患者运动耐量改善可能有限。

局限性

  • 本研究为ORBITA-2试验的事后分析,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ORBITA-2 (Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) was the first randomized placebo-controlled trial to show the efficacy of percutaneous coronary intervention (PCI) in patients with stable angina and single- or multivessel coronary artery disease without background antianginal medication. Whether the effect is consistent across age groups is unknown. OBJECTIVES: The authors sought to evaluate the interaction between age and symptom and stenosis severity, and the efficacy of PCI on the ORBITA-2 primary and secondary endpoints. METHODS: All patients from the primary ORBITA-2 trial contributed data to this post hoc analysis. For daily symptoms, a bayesian longitudinal Markov model was constructed. For treadmill exercise time, stress echocardiography, and questionnaires, a bayesian ordinal proportional odds model was used, including the prerandomization value and treatment arm, which were allowed to interact with age. RESULTS: The mean age was 64 ± 9 years, ranging from 40 to 82 years. There was little relationship between age and symptom and stenosis severity. In older patients, PCI was more effective for symptom relief (OR: 2.03; 95% CrI: 1.67-2.45; Pr > 0.99) than in younger patients (OR: 1.70; 95% CrI: 1.38-2.15; Pr > 0.99; Pr [interaction] = 0.99). In contrast, the effect of PCI on treadmill exercise time was far greater in younger than in older patients (50-year-old: +125 s [95% CrI: 35.8-215.0 s; Pr > 0.99]; 70-year-old: +31.9s [95% CrI: -12.6 to 78.3; Pr = 0.92]; Pr [interaction] = 0.96). CONCLUSIONS: PCI was effective across all ages in reducing angina frequency. Notably, there was limited improvement in treadmill exercise time in the elderly, challenging its role as a primary endpoint in many antianginal trials. These data should inform cardiovascular clinical trial design to ensure applicability across all ages. (Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina [ORBITA-2]; NCT03742050).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Simader FA, Rajkumar CA, Foley MJ, et al. Association Between Age and PCI Effectiveness in Stable CAD: Secondary Analysis of ORBITA-2. J Am Coll Cardiol. 2026. PMID: 41603507. doi:10.1016/j.jacc.2025.10.086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。